The hepatitis C virus (HCV) is an important contributor to morbidity and mortality in patients co-infected with HIV. Co-infection results in increased HCV replication and more rapid rates of liver disease progression. The effect of HIV combination antiretroviral therapy (cART) on HCV replication has not been studied in depth. To address this issue, we enrolled a small cohort of HCV/HIV co-infected patients into a cART initiation trial and used dynamic modeling combined with evaluation of immune responses and microarray profiles to determine how effective treatment of HIV affects HCV. Treatment with cART resulted in increased HCV replication and increased alanine aminotransferase (ALT) in a subset of patients. Subjects with evidence of hepatic injury (increased ALT) were more likely to have HCV-specific immune responses directed against HCV epitopes. Over time, HCV viral loads declined. Reproducible and biologically important gene expression changes occurred in co-infected patients who underwent successful cART. The effective suppression of HIV by cART initiated a cascade of early and late events in treated patients. Early events involving down-regulation of interferon-stimulated genes may have led to transiently increased viral replication and hepatic injury. At later time points, HCV viral load declined to levels comparable to those seen in the setting of HCV monoinfection. These findings support early antiretroviral therapy in those with HCV/HIV co-infection.
INTRODUCTION
Hepatitis C virus (HCV) co-infection is a frequent cause of significant comorbidities and mortality among those infected with HIV. In the United States, 200,000 to 300,000 people have HCV/HIV co-infection, and worldwide estimates range from 4 to 8 million (1) . HCV/HIV coinfection is not benign and is associated with higher rates of HCV replication, increased hepatocyte injury, more rapid progression of liver disease to advanced fibrosis and cirrhosis, and increased rates of development of hepatocellular carcinoma (2) . The presence of liver injury as evidenced by abnormal levels of serum transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] can limit treatment of HIV (3) .
HCV/HIV co-infection is associated with increased HCV viral load in serum/plasma (4, 5) . This observation has been well described but poorly characterized. Higher HCV viral loads are associated with a delay in HCV clearance after HCV treatment (6) . Furthermore, longitudinal treatment studies demonstrate that a paradoxical increase in HCV viral load after initiation of combination antiretroviral therapy (cART) for HIV occurs in some patients. This appears to be more frequent among those with low CD4 + T cell counts at initiation of cART (7, 8) . The effect of prolonged HIV suppression on HCV is also poorly characterized, with clinical studies describing persistent HCV viral load increases, decreases, or return to pretreatment set-point levels (9) . In some cases, initiation of cART is accompanied by an increase in serum transaminases, often termed an ALT "flare," which may lead clinicians to discontinue or modify cART in response to liver enzyme abnormalities that may be attributed to drug-related hepatotoxicity.
Although the phenomenon of HCV viral load increase and ALT flare after initiation of cART is well documented in clinical trials, the significance of these flares, their relationship to specific and innate immune responses, and the outcome of effective HIV therapy in relation to HCV remain uncharacterized. To address this issue, we embarked on a study of a small prospective cohort of HCV/HIV co-infected patients treated with cART. The study was designed to characterize changes in HCV viral load and ALT after cART initiation; to determine the relationship of these HCV viral load changes to HIV decline, CD4 + T cell rebound, and HCV-specific T cell responses; and to evaluate the broader changes in both virus-specific and cytokine-mediated immune responses that occur after cART initiation. All subjects had HIV in conjunction with HCV genotype 1 infection. They were started on efavirenz, or atazanavir/ritonavir, along with a backbone of tenofovir/ emtricitabine. Viral dynamic modeling was used to characterize the relationship between HIV decline, HCV viral load change, and other immunological and virological parameters.
RESULTS

Study population
Eighteen subjects gave consent for the clinical trial. One subject was classified as a screen failure and was not enrolled. Thirteen of the enrolled subjects were male, and four were female. Most were black, nonHispanic (83%), and the remainder were Caucasian. The mean age was 48 years (range, 24 to 60 years). The median CD4 + T cell count was 346 cell/mm 3 (range, 87 to 576 cell/mm load was 4.47 log 10 copies/ml. The HCV viral load median was 6.29 log 10 IU/ml. Baseline liver biopsy revealed that 12 subjects (70.5%) had early hepatic fibrosis (Metavir F0-F2), whereas the remainder had bridging fibrosis (F3) disease. No patients with frank cirrhosis were enrolled. IL28B gene polymorphisms were also evaluated in patients who provided genetic testing consent (n = 9); 33% had the CC genotype, which is associated with both spontaneous viral clearance and treatment-associated clearance of HCV, and the remainder had CT or TT polymorphisms. All patients provided informed consent, and the study protocols were approved by the Institutional Review Boards at all enrolling sites (University of Cincinnati, Virginia Commonwealth University, and New York University).
Increase in serum ALT, HCV, and relationship to liver histology The doubling of serum ALT from baseline levels met the prestudy definition of a significant ALT abnormality. Overall, 7 of 17 subjects (41.1%) met this criterion. ALT increases ranged from 2 to 10 times baseline levels. ALT increases first appeared at a mean of 15.4 weeks after cART initiation (range, 4 to 32 weeks). Abnormalities in this range persisted through follow-up in only one subject. The peak ALT levels occurred at week 16 of HIV treatment (Fig. 1) . IL28B polymorphisms showed no relationship to ALT flare. A regression model was used to examine factors possibly associated with ALT increase including age, gender, race, baseline HIV and HCV viral loads, baseline and change in CD4 + T cell counts by 24 weeks, and HIV clearance. Only HIV clearance was associated with HCV increase or ALT flare (P = 0.03). Seven subjects underwent repeat liver biopsy after protocol-specified increases in ALT or serum HCV RNA. Liver histology was evaluated and scored in a blinded manner. The necroinflammatory score, a histological measure of the degree of liver necrosis and inflammation, decreased from a median of 7 to 5 (Wilcoxon exact probability = 0.06). Paired comparison of individual patients is presented in Fig. 2 . Fifty-seven percent (four of seven) demonstrated an improvement of one or more points in the necroinflammatory component of the histological scoring system. Two patients were unchanged, and one worsened by one point.
A stepwise linear regression model designed to examine factors associated with the change in necroinflammatory score was developed. After univariate evaluation of a number of factors, the model demonstrated that pre-antiretroviral titers of HCV and HIV, CD4 + T cell count, and pretreatment response to HCV epitopes were important factors and yielded an adjusted r 2 = 0.83. ALT, age, and baseline fibrosis, which were important univariate predictors, fell out of the regression model. High baseline HIV viral load and low pretreatment CD4 + T cell counts were the key predictors of improved necroinflammatory liver biopsy scores, with P values of 0.018 and 0.049, respectively. Although HCVspecific immune responses at baseline strengthened the model, the association failed to reach statistical significance (P = 0.17).
Changes in HCV RNA Four subjects (23.5%) met the study definition of HCV RNA flare increase (>0.5 log 10 increase from baseline). Most of these occurred at week 8 or 12, although there was one late event at week 88. The mean HCV RNA increase among those meeting the HCV flare criterion was 0.65 log 10 IU/ml. One subject with an early ALT flare had a late (week 72) HCV RNA increase greater than 0.5 log 10 IU/ml as well, but the protocol did not allow a second posttreatment liver biopsy. The maximal mean increase in HCV RNA was 0.33 log 10 units in all subjects at any time point, generally occurring within the first 24 weeks after cART initiation. Overall, 82% (14 of 17) of subjects experienced an increased HCV viral load over baseline at one or more time points. This exceeded expectations of normal variation (odds ratio, 5.25; 95% confidence interval, 1.09 to 25.21) . Despite these increases, the overall trend in HCV RNA was to decline from baseline levels. Paired sample data were available for 13 of 17 subjects at week 72. The mean HCV RNA at HCV baseline was 6.38 log 10 IU/ml (SEM, 0.15). At week 72, the mean had decreased by 0.52 log 10 IU/ml (Wilcoxon test, P = 0.025).
Kinetic analysis of HIV viral decline HIV viral load over time, denoted V(t), was fitted with the following two-phase decline model (see Materials and Methods): where V 0 is the baseline viral load, p 0 is a constant, d is the death rate of short-lived HIV-infected cells, d M is the death rate for long-lived HIV-infected cells, and t 0 is the delay until the viral load starts to decline. We ignored an exponential term proportional to the rate of HIV clearance, c, because this only affects the viral kinetics in a minor way during the first half-day of therapy. Data were fitted until the first data point under the limit of detection (LOD) (black dotted line in fig. S1 ), and this data point was fitted in the model assuming that it was equal to half the LOD (this is why the fits are below the data point in some patients). Choosing a value at half the LOD is one recognized means of dealing with left-censored data (10) . Patient CIN04 experienced HIV virologic rebound at week 4 that could not be captured by this model, and therefore, data at weeks 4 and 8 were not included in the fitting procedure, and the parameters d M and p 0 could not be estimated for this patient. All other patients presented a biphasic viral decay that could be well fitted by our model. Viral kinetics parameters were in line with estimates from the literature for monoinfected patients (fig. S2 and Table 1 ), which supports the hypothesis that infection with HCV does not significantly affect the early kinetics of HIV decline after initiation of cART (11) (12) (13) . Last, the loss rate of short-lived HIV-infected cells, d, was correlated with both baseline plasma HIV RNA viral levels (P = 0.076) and the loss rate of long-lived HIV-infected cells, d M (P = 0.08). Our model assumes that treatment is 100% effective in blocking new infections.
Using this assumption, the first and the second slopes of viral decline were exactly equal to the loss rates of long-and short-lived infected cells, respectively. The correlation between the two loss rates suggested that the slopes of viral decline were also related to the effectiveness of the antiviral treatment, which may not be 100% efficient (14) . More detailed analysis of HIV models showed that each slope of viral decline was roughly proportional to cART effectiveness. Patients with a flare in ALT levels (doubling from baseline) in the first 20 weeks of treatment (n = 6) tended to have lower slopes of viral decline (Table 1) .
HCV and HIV kinetics
Granger causality: The change in HIV RNA may induce a change in HCV RNA. First, we explored a possible relationship between HIV and HCV viral kinetics. For that purpose, we introduced the notion of Granger causality originally developed in economics to quantify a causal effect from time series observations (15) . It is based on the simple idea that causes precede effects. Formally, X is said to Grangercause Y if its past value can help to predict the future value of Y beyond what could have been done with the past value of Y only. Although Granger causality tests are now widely used in many branches of science, a positive result does not prove causality, although it suggests a stronger relation between variables than simple correlation.
When restricting the analysis to data until day 7, we found that in 14 of 16 patients, HIV RNA was more likely to Granger-cause Table 1 . HIV viral kinetics estimated by fitting Eq. 1 to each patient's viral load. NA, not applicable. changes in HCV RNA than vice versa, and in all these patients, this value was statistically significant at the level of 10% (table S1) . However, when including data until week 12, the results were not significant, possibly due to the fact that a large proportion of HIV RNA data are under the LOD and that this approach works poorly when time points are not equally spaced, as is the case in this study. Overall, this statistical approach supports the hypothesis that HIV treatment has an impact on HCV RNA. However, it does not tell us anything about the nature of this relationship. Using a modeling approach, we aimed next to characterize this correlation.
Correlation between changes in HCV viral load at different time points and HIV viral kinetics. Figure S3 displays the correlation between the parameters of HIV viral decline, namely, d and d M , and the changes in HCV RNA from baseline at different time points (weeks 1, 4, and 8 for d and weeks 4, 8, and 48 for d M ). These time points were chosen because they represent different periods in HCV kinetics (see changes over time in fig. S1 ). A rapid initial HIV decline (that is, high d) was correlated with an early change in HCV RNA at weeks 1 and 4 (P = 0.10 and 0.048, respectively), and this change was a decline. Further, the loss rate of long-lived HIV-infected cells, d M , was found to be significantly correlated with HCV RNA changes at week 4 (P = 0.028). Last, the maximal HCV RNA decline from baseline in the first 4 weeks of treatment was significantly correlated with d (P = 0.04) but not with d M (fig. S4 ). No significant correlations were found using later data points (week 12, week 40, and so on), during which changes in HCV viral load compared to baseline levels were more substantial ( fig. S3 ).
T cell-specific responses and relation to change in HCV viral load To identify the role of the antigen-specific immune responses in the induction of ALT and/or HCV flare, we evaluated HCV-specific and nonspecific immune responses in 15 of the HCV/HIV co-infected patients enrolled in the study before cART therapy, and correlated these data with the clinical and laboratory findings. We monitored HCV-specific and nonspecific immune responses using interferon-g (IFN-g) enzymelinked immunospot (ELISPOT) assays at baseline before initiation of cART therapy. Additionally, correlations between the antigen-specific immune responses and viral loads, CD4 + T cell counts, and ALT levels were evaluated. During cART therapy, the magnitude (both mean number of antigen-specific spots/10 6 cells and total proportion with >55 spots/10 6 cells) of the HCV-specific immune responses at baseline in the subjects with ALT flare was significantly higher compared to subjects who did not show ALT flare (P < 0.005) ( fig. S5B) . A weak positive correlation was found between the HCV viral load and the HCV-specific IFN-l immune responses (r 2 = 0.21, P = 0.0018). Additionally, no significant differences were seen in responses to positive control antigens (CEF control peptides) and nonspecific T cell stimulation (anti-CD3) at baseline ( fig. S5A ).
Effect of HIV treatment on gene array profiles
To evaluate patient responses to cART, we used genome-wide expression profiling of patients' peripheral blood mononuclear cells (PBMCs) before and after treatment initiation (baseline and week 24). RNA quality for this analysis at both time points was acceptable for a subset of eight subjects. Gene expression changes were analyzed on the basis of the change in expression of each measured transcript per patient. Genes with moderately high absolute expression [robust multiarray average (RMA) >5.5] that consistently increased or decreased in their relative expression in at least two or three patients were considered, and this pool of genes was then compared statistically using both parametric and nonparametric t tests. This approach allowed for the identification of 341 probe sets that could be mapped to 115 genes whose expression increased (response-up) and 157 whose expression decreased (responsedown) irrespective of flare or HCV increase, and to the top most differentially regulated genes (heat map in Fig. 3 and table S2 ). Gene set enrichment (16) and biological network-based analyses (17) (fig. S6 ) revealed enrichment among down-regulated genes for their functional association with IFN signaling, response, and resistance to viral infection and for genes whose promoters contained conserved motifs corresponding to IFN response factor binding elements. Genes that were up-regulated after cART were enriched for gene functions associated with increased translation and normal CD4 + and CD8 + T cell responses corresponding to CD4 + T cell rebound. Analysis of serum cytokine responses revealed that cART initiation was associated with significant decreases in tumor necrosis factor-a (TNF-a) (P = 0.0004) and IFNg-inducible protein-10 (IP-10) (P < 0.0001). There was also a trend toward decreased levels of circulating IFN-a.
Despite the similarity of expression changes across all patients undergoing cART with respect to the above gene sets, the two individuals profiled who exhibited a rise in their HCV titers showed a remarkably different pattern of gene expression. As shown in Fig. 3 , the prominent pattern was the activation of genes associated with antigen processing, vacuolar membranes, and major histocompatibility complex class II receptors, from screening to post-therapy in the individuals whose HCV titers rose. Although there were only two individuals profiled out of seven who exhibited this pattern, the relative connectivity of these genes was highly significant.
In an effort to link the results of the gene profiling with changes in cART-associated HIV and HCV viral loads, univariate analysis followed by stepwise linear regression was performed. We focused on determining the relationship between the predominant pattern of downregulation of IFN-mediated gene expression and the observed viral load outcomes. Univariate analysis suggested correlations with ALT, age, baseline HCV and HIV titers, baseline CD4 + T cell counts, fibrosis stage at entry, IFN-related gene expression, and HCV viral load over the course of the post-cART period. However, all factors, except IFNstimulated gene (ISG) down-regulation, were not significant when linear regression analysis was applied. ISG down-regulation was highly significant (P = 0.0063).
DISCUSSION
Several previous studies have suggested a link between initiation of HIV antiretroviral therapy and changes in HCV viral load. Most have reported transient increases in HCV RNA during the first 24 weeks of treatment (7, 9). Chung et al. suggested that this paradoxical effect was most commonly observed in those with low CD4 + T cell counts before cART initiation. We observed transient increases in HCV RNA in a subset of treated patients. This was frequently accompanied by increases in serum ALT levels. The highest mean increase in ALT was observed at week 16. Such increases have often been classified as "drug hepatotoxicity" and may result in drug discontinuation by clinicians in clinical practice, often mirroring toxicity guidelines used in clinical trials of therapeutic agents (18) . However, these abnormalities are rarely characterized with evaluation that includes liver histology. Historically, ALT abnormalities <5× the upper limit of normal (ULN) are ignored, and those greater than 5× ULN (grade 3 toxicity) require attribution of causality and, in some cases, drug discontinuation. Except for cases where liver biopsy was performed to evaluate putative severe drug toxicity in clinical practice, we are not aware of any trial that systematically performed liver biopsy evaluation on patients with ALT and/or HCV flare as defined in this study. The liver biopsy data were surprising and show a strong trend toward improvement in hepatic necroinflammatory scores, supporting the concept that HIV treatment may be beneficial to the liver in the setting of HCV infection. This trend was most pronounced in those with the lowest CD4 + T cell counts and the higher HIV viral loads. This observation may appear to be counterintuitive. However, a number of studies have supported an inverse relationship between low CD4 + T cell counts and increased inflammation. Benhamou et al. first reported that low CD4 + T cell counts were associated with greater necroinflammatory activity in HIV/HCV co-infected patients versus those infected with HCV alone (19, 20) . Pascual-Pareja et al. specifically examined the relationship of HIV suppression to necroinflammatory activity (21). They noted that the level of hepatic inflammation was strongly associated with active HIV replication in the absence of cART. Although the mechanism of this is unclear, it has been suggested that gp120 may drive HCV replication, increasing hepatic injury (22) . gp120 levels in plasma do not necessarily correlate with HIV viral load (23) . An alternative hypothesis is that HIV infection directly drives production of localized proinflammatory cytokines in the liver, leading to necroinflammation, and effective HIV suppression abrogates this process (24) . Because liver biopsy occurred up to 2 weeks after flare identification, it is possible that early findings of infected hepatocyte clearance associated with HCV-specific immune responses (for example, increased apoptotic bodies) may have been missed. The overall degree of chronic inflammation that comprises the necroinflammatory score was decreased by the broad local down-regulation of the proinflammatory cascade.
The observation that HIV suppression reduces inflammation and subsequent hepatic fibrosis formation is supported by large epidemiological studies showing lower liver-related morbidity and mortality among those receiving effective antiretroviral therapy (25) . It is also supported by data from the HCV/HIV SLAM-C (Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients) study, which failed to find fibrosis progression among a group of HIVsuppressed patients (26) . These findings strongly support the early use of cART in those with HCV/HIV co-infection as a way to protect the liver from injury. Furthermore, our data suggest that ALT flare does not necessarily represent drug-related hepatotoxicity, and the failure to recognize this possibility could result in cART discontinuation, which could actually be harmful to the patient in the long term.
The weak positive but statistically significant correlation between baseline HCV-specific immune responses and the HCV viral load indicates that HCV viral load may stimulate the induction of HCV-specific immune responses. However, these immune responses are not effective in lowering HCV viral load. Kang et al. also noted that HCV-specific T cell response recovery after cART initiation may lead to transient liver injury (27) . It is possible that our observations of HCV-specific immune responses were not mirrored by intrahepatic immune responses present in the microenvironment of the liver. However, despite this caveat, a clear relationship between peripheral HCV-specific responses in PBMCs and early increases in viral load was observed. Although we studied IFN-g ELISPOT, additional information may be gleaned by examination of other cytokine responses [for example, interleukin-2 (IL-2)]. Future studies will include analysis of other cytokines. Fig. 3 . Gene expression changes after cART treatment of HIV/HCV co-infected patients. Heat map of gene expression changes that occurred after cART treatment in HIV/HCV co-infected patients. Gene expression changes are depicted as the ratio of gene expression at 24 weeks after cART compared to baseline gene expression before treatment. Genes that decrease from their baseline values are blue, and those that increase are red. Four clusters are indicated corresponding to genes that (i) increased or (ii) decreased after cART treatment in the patients whose HCV titers rose, (iii) that increased in response to cART for nearly all patients, and (iv) that decreased in response to cART. A change in expression pattern can be seen between the first six patients on the left who had a drop in HCV titer compared to the two patients on the right who had a rise in titer.
The mechanistic link between cART effectiveness and HCV RNA decline remains unclear. However, we have observed significant down-regulation of ISGs after initiation of cART and postulate that this initially results in loss of IFN-mediated control of HCV replication, resulting initially in increased HCV viral loads. In the setting of a preexistent HCV-specific cellular immune response, increased cell clearance leads to transient increases in serum ALT levels (that is, immunologically mediated hepatic injury or immune reconstitution inflammatory syndrome). However, global up-regulation of CD4, CD8, and a-b T cell activity leads to broad suppression of HCV viral replication over time. The decrease in HCV RNA is roughly equivalent to the median increase in HCV titer observed in clinical cohorts with HIV infection compared to those with HCV monoinfection (4, 5, 28) . Although several studies have suggested that immune reconstitution after cART does not restore the immune status present before HIV infection, it appears that effective cART returns HCV/HIV co-infected patients to a functional HCV monoinfection state, at least in terms of HCV viral load. This has implications for HCV treatment response. We acknowledge that sample size is a limitation of this type of indepth analysis, but believe that these data support emerging concepts that early HIV control with antiviral agents represents the best initial approach to management of HCV/HIV co-infected patients and is congruent with recent recommendations for early HIV treatment made by expert consensus groups (29) .
MATERIALS AND METHODS
Study design
Patients with HCV and HIV co-infection were enrolled in a clinical trial designed to intensively evaluate the effects of initiation of antiretroviral therapy on HCV replication and liver injury. Briefly, after providing informed consent, subjects greater than 18 years of age with HCV RNA genotype 1 and HIV were enrolled. All subjects had a liver biopsy consistent with chronic hepatitis within 1 year of enrollment and were HIV antiretroviral treatment-naïve or off cART for at least 3 months. They were required to be sensitive to the proposed study drugs. Key exclusion criteria included baseline hemoglobin <9 g/dl, pregnancy, concurrent infection with hepatitis B or presence of another liver disease, decompensated liver disease, active thyroid disease, creatinine clearance <50 ml/min, recent use of corticosteroids or immunomodulatory drugs, current HCV therapy, or any condition that might preclude study participation. Subjects were treated with efavirenz (60-mg oral dose once daily) and tenofovir/emtricitabine (once daily). Subjects unable or unwilling to take efavirenz were permitted to substitute atazanavir (300 mg/day) boosted with ritonavir (100 mg/day). Study subjects were followed for 96 weeks after initiation of study medications. Early viral dynamic sampling was performed at hours 0 (baseline), 2, 4, 6, 9, 12, 18, 24, 48, 72, 96 , and 168 (7 days) from initiation of first dose of cART. Additional samples were collected upon doubling of ALT from baseline or a viral load increase of >0.5 log 10 IU/ml of HCV RNA. Repeat liver biopsies were obtained when ALT or HCV RNA increased to specified levels.
Viral kinetic modeling
Previous studies of HIV dynamics demonstrated that after cART is initiated, there are two phases of HIV-1 RNA decay: an initial rapid, exponential decline of 1 to 2 logs, in which productively infected short-lived cells are lost, followed by the second phase, which is characterized by a slower decline, where long-lived infected cells are lost (11, 30, 31) . HIV viral kinetics were thus fit using the previously developed long-lived infected cell model that considers short-and longlived productively infected cells using the following equation:
where V 0 is the baseline viral load, d is the death rate of short-lived productively infected cells, d M is the death rate of long-lived productively infected cells, c is the rate of virion clearance, t 0 is the time at which the viral load starts decaying (that is, a pharmacological delay), and A and C are constants defined by Perelson et al. (11) . We fixed the half-life of free virus, c, to the previously estimated value c = 23 day −1 (32) . With this value of c, the last exponential term in Eq. 1 rapidly becomes negligible and thus was ignored.
Evaluation of immune response using ELISPOT assay Isolation of PBMCs. PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation and were then used either fresh or cryopreserved in cell-freezing medium [90% fetal bovine serum (FBS; BioWhittaker) and 10% dimethyl sulfoxide (Sigma)]. They were stored in liquid N 2 or at −80°C until used to test for cytokine production as described below. Before performing any assay with frozen samples, PBMCs were thawed, washed twice in complete RPMI 1640 medium supplemented with penicillin/streptomycin [potassium penicillin (10,000 U/ml) and streptomycin sulfate (10,000 mg/ml)], 1% sodium pyruvate, 0.1% 2-mercaptoethanol, and 10% heat-inactivated FBS. Viability was determined by trypan blue exclusion. Fresh and frozen PBMCs have provided comparable results using ELISPOT immunoassays in our laboratory as previously reported (33) .
Human leukocyte antigen (HLA) class I typing for the patients was performed at Hoxworth Blood Center (Cincinnati, OH) using sequence-specific oligonucleotide probes. Allele-level HLA typing was performed by sequence-based typing.
Antigens. Four pooled HCV peptides were obtained from the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program (HCV type 1a H77) (18-mer peptides) (catalog no. 7620), as well as dominant HLA peptides according to the HLA class I of the patient. Each peptide was used at the final concentration of 1 to 10 mg/ml. CEF control peptide pool (catalog no. 9808) was obtained from the NIH AIDS Research and Reference Reagent Program and contains pool of 32 cytomegalovirus, Epstein-Barr virus, and influenza virus dominant peptides, which stimulate CD8 + T cells and were used at a concentration of 1 to 10 mg/ml.
IFN-g ELISPOT assay
The ELISPOT assay has the advantage of being able to specifically enumerate cells as well as quantify cytokine secretion patterns. The assay procedures are described elsewhere (33) . Briefly, freshly prepared PBMCs (1 × 10 5 cells per well) were incubated in duplicate cultures in the ELISPOT plates coated with anti-IFN-g antibody and incubated for 16 hours with or without antigens at the proper concentration in complete RMPI 1640 medium. Positive and negative controls were anti-CD3, CEF, and medium alone, respectively. The plate was incubated for 16 to 18 hours, developed until spots appeared in the wells, and then rinsed with tap water. The number of spots per well was scored using an automated ELISPOT reader (Cellular Technology Ltd.). Our previous studies suggested that thawed PBMCs with an average number of >10 3 spot-forming units (SFUs)/10 6 cells after anti-CD3 stimulation are functionally viable (34) . Averaged numbers of SFUs in control wells were subtracted from antigen-stimulated wells to correct for spontaneous cytokine production and expressed per 10 6 cells. Positive HCV antigen-specific responses were defined by a mean result of >55 SFUs/10 6 PBMCs. This cutoff value was derived from the work by testing of multiple healthy controls in this study and coincides with results previously reported by our group and others (35) (36) (37) .
RNA preparation for gene array profiling PBMC samples were thawed slowly and washed with RPMI 1640 medium and Dulbecco's phosphate-buffered saline. After washing, total RNA was extracted using RNeasy Mini Kit spin-column technology, as outlined in the manufacturer's protocol (Qiagen). Samples were eluted with 30 ml of ribonuclease-free water. RNA was treated with TURBO DNA-free kit (Ambion) to remove DNA contamination.
Microarray and genomic data analysis Gene expression from whole-blood RNA was measured via Affymetrix PrimeView microarrays and the Affymetrix-specified 3′ untranslated region-based labeling method. The microarray quality control factors for the samples were examined using the Affymetrix Expression Console Program. CEL files were analyzed using the RMA normalization and expression level quantitation algorithm. Probe sets were filtered to identify those with absolute expression in at least two samples above RMA >5.5, and then for their differential expression in their treated versus baseline per patient using Benjamini-Hochberg-corrected P < 0.05. The resulting list of probe sets was subjected to hierarchical clustering of relative change from baseline values per patient to identify patients and genes that exhibited similar relative gene expression change patterning (heat map). Gene set enrichment and network connectivity analyses were carried out using http://toppcluster.cchmc.org, and features were selected that reflected statistically significant features within category and that maximally connected between categories. In this manner, a network was generated using Cytoscape to illustrate the interactions and shared properties of up-and down-regulated genes on the basis of known pathways, biological processes, mutant effects phenotypes, conserved promoter cis elements, protein-protein interactions, etc. The network figures were generated on the basis of clustering the interactions and features that were shared among genes whose expression was decreased or increased in nearly all patients after their completion of the treatment regimen. Clusters were analyzed by group in regression models. For example, the ISG cluster contained IFN-alfa, IFN-induced proteins, 2′-5′-oligoadenylate synthase, and other markers of the ISG group.
Statistical methods
Parametric and nonparametric methodologies including Student's t test, c 2 test, and Fisher's exact test were used for comparisons as described in Results. Univariate analysis and stepwise linear regression models were used to explore relationships of factors associated with key outcomes. Data were analyzed using Statistix 9.0/10.0 (Analytical Software). Statistical significance was set at an a = 0.05 using a twotailed hypothesis unless otherwise specified.
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